Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 4/20 | 0.55 |
| ▸ | CA1 | P00915 | 3/20 | 0.55 |
| ▸ | CA9 | Q16790 | 2/20 | 0.55 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.52 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.51 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.51 |
| ▸ | LPL | P06858 | 5/20 | 0.50 |
| ▸ | LIPG | Q9Y5X9 | 5/20 | 0.50 |
| ▸ | NAMPT | P43490 | 1/20 | 0.47 |
| ▸ | F11 | P03951 | 2/20 | 0.46 |
| ▸ | F2 | P00734 | 1/20 | 0.46 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.46 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.46 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16947897 | 0.93 | LPL (0.51) | CA2CA1CA9AAK1PRMT5 | |
| SCHEMBL15585542 | 0.92 | CA2 (0.50) | CA2CA1CA9AAK1PRMT5 | |
| SCHEMBL22767308 | 0.92 | LPL (0.53) | CA2CA1CA9AAK1PRMT5 | |
| SCHEMBL16169739 | 0.88 | PRMT5 (0.48) | CA2CA1CA9AAK1PRMT5 | |
| SCHEMBL169651 | 0.87 | PRMT5 (0.58) | CA2CA1CA9AAK1PRMT5 | |
| SCHEMBL2144320 | 0.86 | LIPG (0.51) | CA2CA1CA9AAK1PRMT5 | |
| SCHEMBL1990625 | 0.84 | CA1 (0.54) | CA2CA1CA9AAK1PRMT5 | |
| SCHEMBL15805934 | 0.83 | PRMT5 (0.46) | CA2CA1CA9AAK1PRMT5 | |
| SCHEMBL15919266 | 0.83 | AAK1 (0.61) | CA2CA1CA9AAK1PRMT5 | |
| SCHEMBL16947773 | 0.82 | DGAT1 (0.50) | CA2CA1CA9AAK1PRMT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 126 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2970176-B1 | MOLECULES HAVING CERTAIN PESTICIDAL UTILITIES, AND INTERMEDIATES, COMPOSITIONS, AND PROCESSES RELATED THERETO | CORTEVA AGRISCIENCE LLC (US) | 2023-10-25 | — | — | EP | disclosed |
| EP-2970176-B1 | MOLECULES HAVING CERTAIN PESTICIDAL UTILITIES, AND INTERMEDIATES, COMPOSITIONS, AND PROCESSES RELATED THERETO | CORTEVA AGRISCIENCE LLC (US) | 2023-10-25 | — | — | EP | disclosed |
| WO-2023153504-A1 | NUCLEIC ACID DELIVERY MATERIAL | 国立大学法人東海国立大学機構 | 2023-08-17 | — | — | WO | disclosed |
| US-20230167073-A1 | ARYL OR HETEROARYL DERIVATIVE | TEIJIN PHARMA LIMITED (JP) | 2023-06-01 | — | — | US | disclosed |
| CN-115996910-A | Aryl or heteroaryl derivatives | 帝人制药株式会社 | 2023-04-21 | — | — | CN | disclosed |
| EP-4137481-A1 | ARYL OR HETEROARYL DERIVATIVE | Teijin Pharma Limited (JP) | 2023-02-22 | — | — | EP | disclosed |
| US-20230029009-A1 | CHEMICAL COMPOUNDS | BLUE OWL CAPITAL CORPORATION, AS NEW AGENT | 2023-01-26 | — | — | US | disclosed |
| US-20230029009-A1 | CHEMICAL COMPOUNDS | BLUE OWL CAPITAL CORPORATION, AS NEW AGENT | 2023-01-26 | — | — | US | disclosed |
| US-11459331-B2 | Chemical compounds | AVISTA PHARMA SOLUTIONS, INC. (US) | 2022-10-04 | — | — | US | disclosed |
| EP-4026832-A1 | PIPERIDINE DERIVATIVES AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7 | Almac Discovery Limited (GB) | 2022-07-13 | — | — | EP | disclosed |
| US-20090318436-A1 | Fused heterocyclic derivatives and methods of use | AMGEN INC. (US) | 2009-12-24 | — | — | US | disclosed |
| US-20090264468-A1 | Methods for treating a disease in which Rho kinase is involved | UBE INDUSTRIES, LTD. (JP) | 2009-10-22 | — | — | US | disclosed |
| WO-2009091374-A2 | FUSED HETEROCYCLIC DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2009-07-23 | — | — | WO | disclosed |
| WO-2009091374-A2 | FUSED HETEROCYCLIC DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2009-07-23 | — | — | WO | disclosed |
| US-7563906-B2 | Indazole derivatives | UBE INDUSTRIES, LTD. (JP) | 2009-07-21 | — | — | US | disclosed |
| US-20090124609-A1 | Fused heterocyclic derivatives and methods of use | AMGEN INC. (US) | 2009-05-14 | — | — | US | disclosed |
| US-20090124609-A1 | Fused heterocyclic derivatives and methods of use | AMGEN INC. (US) | 2009-05-14 | — | — | US | disclosed |
| US-20090124609-A1 | Fused heterocyclic derivatives and methods of use | AMGEN INC. (US) | 2009-05-14 | — | — | US | disclosed |
| US-20070129404-A1 | Novel indazole derivatives | UBE INDUSTRIES, LTD. (JP) | 2007-06-07 | — | — | US | disclosed |
| EP-1679308-A1 | NOVEL INDAZOLE DERIVATIVE | Ube Industries, Ltd. (JP) | 2006-07-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318436-A1 | Fused heterocyclic derivatives and methods of use | HGF, HGFAC, MET | CA2 3345/4885CA1 2847/4885CA9 1334/4885 |
| US-20230167073-A1 | ARYL OR HETEROARYL DERIVATIVE | ARRB1, NR3C2, TRPC6 | CA2 2861/4885CA1 4852/4885CA9 4469/4885 |
| US-11459331-B2 | Chemical compounds | PTGER4, PTGES, PTGES2 | CA2 2133/4885CA1 4486/4885CA9 3503/4885 |
| US-20230029009-A1 | CHEMICAL COMPOUNDS | PTGER4, PTGES, PTGES2 | CA2 2133/4885CA1 4486/4885CA9 3503/4885 |
| US-20090264468-A1 | Methods for treating a disease in which Rho kinase is involved | RHOA, ROCK1, RHOT2 | CA2 743/4885CA1 3375/4885CA9 3299/4885 |
| US-20070129404-A1 | Novel indazole derivatives | CIT, ROCK1, ROCK2 | CA2 1567/4885CA1 4768/4885CA9 4437/4885 |
| US-20090124609-A1 | Fused heterocyclic derivatives and methods of use | HGF, HGFAC, MET | CA2 3345/4885CA1 2847/4885CA9 1334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.